argenx reports Q3 sales growth of 54 percent while argenx stock costs EUR 758.70

Published on 10/22/2026 at 11:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

argenx reported USD 1.7 billion in third-quarter product sales, up 54 percent year over year. argenx stock costs EUR 758.70 on October 22, 2026.

argenx expands quarterly sales

argenx reported USD 1.7 billion in third-quarter product sales on October 22, 2026.
VYVGART sales grew 54 percent year over year in the third quarter of 2026.
argenx stock trades at EUR 758.70 at 11:07 a.m. CEST at Lang & Schwarz on October 22, 2026.
Phase 3 empasiprubart data are expected in December 2026.

Schwarz-Weiß-Reportagefoto: Forscherin beugt sich konzentriert über ein Mikroskop im Immunologie-Labor, dramatisches Chiaroscuro-Licht, körnige Filmtextur — Argenx NL0010832176 Reportagefoto in Schwarz und Weiß zeigt Wissenschaftlerin bei der Autoimmun-Forschung am Mikroskop, Illustration mit AI erstellt.

argenx (ISIN NL0010832176) reported USD 1.7 billion in global product net sales for the third quarter of 2026, an increase of 54 percent from the same period in 2025. According to GlobeNewswire on October 22, 2026, the company also expects combined research and development and selling, general and administrative expenses of approximately USD 4.0 billion for full-year 2026.

VYVGART drives quarterly growth

The result keeps VYVGART at the center of the investment case. Product net sales reached USD 1.7 billion in the third quarter of 2026, compared with USD 1.1 billion in the third quarter of 2025, while total operating income rose to USD 1.8 billion from USD 1.2 billion.

argenx reported operating profit of USD 486 million for the third quarter of 2026, versus USD 346 million a year earlier. Profit for the period rose to USD 506 million from USD 344 million, while basic earnings per share increased to USD 8.07 from USD 5.61, according to GlobeNewswire.

What comes next for the pipeline?

The next quantified catalyst is the Phase 3 EMPASSION readout for empasiprubart in multifocal motor neuropathy, which argenx expects in December 2026. The company also said FB102 is advancing to Phase 3 in celiac disease and that a supplemental application for VYVGART Hytrulo in immune-mediated necrotizing myopathy remains on track for submission by year-end 2026.

Three recent company milestones

On October 15, 2026, argenx announced a third-quarter results webcast scheduled for October 22, 2026 at 2:30 p.m. CET. On October 20, 2026, RBC Capital cut its target for argenx from USD 1,100 to USD 1,025 while retaining an Outperform rating, according to Investing.com. On October 22, 2026, argenx reported USD 1.7 billion in third-quarter product sales and 54 percent year-over-year growth.

Dates investors can track

argenx expects the empasiprubart Phase 3 data in December 2026. The company has scheduled full-year 2026 results and a fourth-quarter business update for February 25, 2027, according to the October 22 release.

Growth meets clinical execution

The figures show a business with rapidly expanding commercial sales, but the pipeline still supplies the next valuation tests. Cash, cash equivalents and current financial assets totaled USD 3.7 billion on September 30, 2026, down from USD 4.4 billion on December 31, 2025 after the Forte Biosciences acquisition.

argenx was trading at EUR 758.70 at Lang & Schwarz on October 22, 2026 at 11:07 a.m. CEST. The primary listings are Euronext Brussels and Nasdaq, and the finance profile identifies the company as a healthcare biotechnology issuer. The market capitalization was USD 56.0 billion as of October 21, 2026.

The further course of trading is shown by the continuously updated real-time quote of argenx stock.